Cover Image

Plasma hyaluronic acid level as a prognostic and monitoring marker of metastatic breast cancer

Conventional tumor markers have limited value for prognostication and treatment monitoring in metastatic breast cancer (MBC) patients and novel circulating tumor markers therefore need to be explored. Hyaluronic acid (HA) is a major macropolysaccharide in the extracellular matrix and is reported to...

Full description

Saved in:
Bibliographic Details
Main Authors: Peng, Cike (Author) , Wallwiener, Markus (Author) , Cuk, Katarina (Author) , Modugno, Caroline (Author) , Heil, Jörg (Author) , Marmé, Frederik (Author) , Madhavan, Dharanija (Author) , Nees, Juliane (Author) , Schott, Sarah (Author) , Sohn, Christof (Author) , Schneeweiss, Andreas (Author) , Yang, Rongxi (Author) , Burwinkel, Barbara (Author)
Format: Article (Journal)
Language:English
Published: 2016
In: International journal of cancer
Year: 2015, Volume: 138, Issue: 10, Pages: 2499-2509
ISSN:1097-0215
DOI:10.1002/ijc.29975
Online Access:Verlag, Volltext: https://doi.org/10.1002/ijc.29975
Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.29975
Get full text
Author Notes:Cike Peng, Markus Wallwiener, Anja Rudolph, Katarina Ćuk, Ursula Eilber, Muhabbet Celik, Caroline Modugno, Andreas Trumpp, Jörg Heil, Frederik Marmé, Dharanija Madhavan, Juliane Nees, Sabine Riethdorf, Sarah Schott, Christof Sohn, Klaus Pantel, Andreas Schneeweiss, Jenny Chang‐Claude, Rongxi Yang and Barbara Burwinkel
Description
Summary:Conventional tumor markers have limited value for prognostication and treatment monitoring in metastatic breast cancer (MBC) patients and novel circulating tumor markers therefore need to be explored. Hyaluronic acid (HA) is a major macropolysaccharide in the extracellular matrix and is reported to be associated with tumor progression. In our study, we investigated plasma HA level with respect to progression free survival (PFS) and overall survival (OS), as well as the treatment monitoring value in MBC patients. The prognostic value of plasma HA level was investigated in a discovery cohort of 212 MBC patients with 2.5-year follow-up and validated in an independent validation cohort of 334 patients with 5-year follow-up. The treatment monitoring value of plasma HA level was investigated in 61 MBC patients from discovery cohort who had been radiographically examined after first complete cycle of chemo therapy. We found a robust association between high plasma HA level and poor prognosis of MBC patients in both discovery (pPFS = 7.92 × 10−6 and pOS = 5.27 × 10−5) and validation studies (pPFS = 3.66 × 10−4 and pOS = 1.43 × 10−4). In the discovery cohort, the plasma HA level displayed independent prognostic value after adjusted for age and clinicopathological factors, with respect to PFS and OS. Further, the decrease of plasma HA level displayed good concordance with treatment response evaluated by radiographic examination (AUC = 0.79). Plasma HA level displays prognostic value, as well as treatment monitoring value for MBC patients.
Item Description:Online 19 December 2015
Gesehen am 11.09.2019
Physical Description:Online Resource
ISSN:1097-0215
DOI:10.1002/ijc.29975

Similar Items